Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Jennifer M. Johnson, a director of Thermo Fisher Scientific Inc. (TMO), was credited with 67.31 Phantom Stock Units on September 27, 2025 under the issuer's Deferred Compensation Plan for Directors. Each unit is convertible into one share of common stock on a 1-for-1 basis and the units were credited at a stated price of $464.24 per unit. The units are distributable as stock when the director ceases service or upon a change of control. The filing notes the reporting person is an executive at Franklin Resources, Inc., and that Franklin Templeton subsidiaries may hold Thermo Fisher shares in client accounts; the reporting person disclaims beneficial ownership of those third-party holdings.
Thermo Fisher is offering multiple series of unsecured senior notes to be issued in global book-entry form through DTC, with interest payable semi-annually beginning in 2026. The notes will rank equally with Thermo Fisher's other unsecured senior debt and senior to any subordinated debt; they will be structurally subordinated to subsidiary indebtedness and effectively subordinated to any future secured debt. As of June 28, 2025, Thermo Fisher and its subsidiaries had approximately $35.23 billion of consolidated indebtedness, $5.00 billion of revolver availability and subsidiaries had $6.99 billion of indebtedness to which the notes would be structurally subordinated. The prospectus describes optional redemption mechanics, a 101% repurchase obligation upon a Change of Control Triggering Event, trustee (The Bank of New York Mellon Trust Company, N.A.), governing law (New York) and various tax and withholding provisions. Several specific offering terms (aggregate amounts, coupon rates, exact maturities and some dates) are redacted in the provided text.
Marc N. Casper, Chairman & CEO of Thermo Fisher Scientific (TMO), reported option exercise and market sales on 09/05/2025 under a Rule 10b5-1 plan. The filing shows the exercise or acquisition of 400 shares at an exercise/conversion price of $253.99 and three market dispositions of 200, 100 and 100 shares at $500, $501 and $501.01 respectively.
Beneficial ownership reported after the transactions is 113,762.285 shares. The report discloses indirect holdings of 11,300 shares by the Alison Casper 2020 Irrevocable Trust, 14,608 shares by Floral Park Associates, Inc., and 5,000 shares by MNC 2020 Irrevocable Trust. The transactions were effected pursuant to a 10b5-1 trading plan adopted April 28, 2025.
Form 144 filing for Thermo Fisher Scientific, Inc. (TMO) shows an intended sale of 400 shares of common stock through Fidelity Brokerage Services on 09/05/2025, with an aggregate market value listed as $200,201 and the transaction to occur on the NYSE. The 400 shares were acquired by option grant on 02/26/2019 and payment is indicated as cash on 09/05/2025. The filing also discloses recent sales by Marc N. Casper totaling 28,496 shares across five transactions in August 2025, producing gross proceeds of approximately $13.41 million. The notice includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
Insider transactions by Marc N. Casper, Chairman & CEO of Thermo Fisher Scientific (TMO). The Form 4 reports two open-market disposals on 08/28/2025, selling 686.571 shares and 724.767 shares at $489.74 per share. After those sales the filing shows beneficial ownership reported as approximately 114,487.052 and 113,762.285 shares (direct holdings). The filing also discloses indirect holdings of 11,300 shares through the Alison Casper 2020 Irrevocable Trust, 14,608 shares via Floral Park Associates, Inc., and 5,000 shares via the MNC 2020 Irrevocable Trust. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Casper on 09/02/2025.
Thermo Fisher (TMO) Form 4 — insider dispositions by Sr. VP & CFO Stephen Williamson. The filing reports four open-market sales on 08/28/2025 totaling 783.273 shares at $489.74 per share. After these transactions, Williamson directly held 32,320.193 shares and is noted as indirectly beneficially owning 12,674 shares through a SLAT, with a disclaimer that he disclaims beneficial ownership except for any pecuniary interest. The form is signed by an attorney-in-fact on 09/02/2025.
Michael D. Shafer, Executive Vice President of Thermo Fisher Scientific, filed a Form 4 disclosing four dispositions of the issuer's common stock on 08/28/2025. Each transaction is reported with Transaction Code F and a per-share price of $489.74. The reported share decreases are 145.051, 162.457, 176.478 and 114.106 shares, leaving a final beneficial ownership of 18,730.8026 shares after the last reported sale. The filing notes inclusion of 49.871 shares acquired under the company employee stock purchase plan on May 15, 2025. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Shafer on 09/02/2025. The document identifies Mr. Shafer as an officer (Executive Vice President) of the issuer.
Frederick M. Lowery, Executive Vice President of Thermo Fisher Scientific (TMO), reported multiple disposals of common stock on 08/28/2025 at a price of $489.74 per share. The Form 4 shows four separate disposition entries totaling 667.718 shares disposed (175.028 + 187.116 + 186.632 + 118.942) and remaining direct beneficial ownership reported in fractional amounts (14,860.0624; 14,672.9464; 14,486.3144; 14,367.3724 across lines). The filing also reports indirect holdings of 1,174.88 shares through a 401(k) plan and 5.036 shares via a limited liability company, with a disclaimer of beneficial ownership for the LLC position.
Michel Lagarde, Executive Vice President & COO of Thermo Fisher Scientific (TMO), reported multiple open-market sales on 08/28/2025. The Form 4 shows four dispositions totaling 961.203 shares sold at $489.74 per share (transaction code F). After these transactions, the report indicates Mr. Lagarde beneficially owns 23,479.909 shares. The filing was signed on behalf of Mr. Lagarde by an attorney-in-fact on 09/02/2025.
Joseph R. Holmes, VP & Chief Accounting Officer of Thermo Fisher Scientific (TMO), reported several equity transactions on Form 4 dated 08/28/2025–08/29/2025. The filing shows multiple dispositions on 08/28/2025 at $489.74 per share (totaling reductions of 37.977 shares when summing 8.512, 10.567, 10.86 and 7.045) and additional transactions on 08/29/2025 including an acquisition of 385 shares at $253.99 and two open-market sales of 100 shares at $492.615 and 285 shares at $492.633. Following these transactions, Holmes beneficially owned 2,318.9815 shares directly. The filing notes 54.846 shares were acquired under the issuer’s employee stock purchase plan on May 15, 2025, and that the 385-share option vested in four installments in 2020–2023.